- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.01. | Acrivon to present ACR-368 endometrial cancer data at ESGO congress | 14 | Investing.com | ||
| 23.01. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress | 10 | GlobeNewswire (USA) | ||
| 09.01. | Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data | 11 | Investing.com | ||
| 08.01. | Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data | 4 | RTTNews | ||
| 08.01. | Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls | 11 | Benzinga.com | ||
| 08.01. | Acrivon reports 52% response rate in serous endometrial cancer trial | 3 | Investing.com | ||
| 08.01. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Acrivon to provide clinical updates on cancer drug candidates | 2 | Investing.com | ||
| 06.01. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast | 2 | GlobeNewswire (USA) | ||
| 17.12.25 | Acrivon to provide clinical data updates for cancer drugs in January | 1 | Investing.com | ||
| 17.12.25 | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates | 2 | GlobeNewswire (USA) | ||
| 17.11.25 | Acrivon Therapeutics stock rating reiterated by Citizens with $13 target | 2 | Investing.com | ||
| 17.11.25 | Acrivon Therapeutics: Citizens bestätigt Rating "Market Outperform" und Kursziel von 13 US-Dollar | 2 | Investing.com Deutsch | ||
| 13.11.25 | Acrivon Therapeutics GAAP EPS of -$0.47 beats by $0.12 | 1 | Seeking Alpha | ||
| 13.11.25 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | 114 | GlobeNewswire (Europe) | Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial... ► Artikel lesen | |
| 13.11.25 | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | Acrivon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10.25 | Acrivon to present data on AI-driven cancer drug development at conference | 2 | Investing.com | ||
| 01.10.25 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 124 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing... ► Artikel lesen | |
| 17.09.25 | Citizens analyst reiterates Market Outperform rating on Acrivon stock | 2 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | Pharma- und Biotech-Aktien 2026: Bayer und BioNTech geben Gas, Bioxyne vor Durchbruch? | ||
| MODERNA | 36,760 | -1,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| NANOREPRO | 1,530 | 0,00 % | NanoRepro ordnet Aufsichtsrat nach außerordentlicher HV neu | Die Aktionäre der NanoRepro AG haben auf der außerordentlichen Hauptversammlung vom 16. Januar 2026 den Aufsichtsrat neu zusammengesetzt. Neu gewählt wurden Gunter Heneis, Michael Herrmann und Konstantin... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,370 | 0,00 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OCUGEN | 1,218 | -0,69 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| MAINZ BIOMED | 1,200 | -1,64 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| INFLARX | 0,750 | +0,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| TEMPUS AI | 51,00 | +0,99 % | Studie von Tempus AI belegt verbesserte Vorhersage für Krebs-Immuntherapie |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -5,05 % bei einem Aktienkurs von 1,785 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.